Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VSV-mIFNβ-NIS
- Development stage
- Preclinical
- Lead developer
- Vyriad
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
VSV-mIFNβ-NIS is a genetically engineered recombinant vesicular stomatitis virus (VSV) that encodes murine interferon-β (mIFNβ) and the sodium iodide symporter (NIS). Designed as an oncolytic virotherapy, it selectively destroys tumor cells with defective interferon pathways while sparing normal tissue. The expression of mIFNβ enhances tumor selectivity and antitumor immune responses and limits VSV replication in healthy cells, increasing safety. The NIS reporter gene enables noninvasive imaging of viral infection and intratumoral distribution. Preclinical studies have demonstrated robust tumor debulking and immune-mediated tumor clearance in murine models, especially in multiple myeloma, with intravenous administration leading to rapid oncolytic activity and sustained antitumor immunity. Clinical studies have been initiated for related constructs in multiple myeloma, lymphoma, acute myeloid leukemia, and endometrial cancer.
- Other names
- vesicular stomatitis virus-murine interferon-β-sodium iodide symporterVSV-mouse IFNβ-NISrecombinant VSV-mIFNβ-NIS
02
Targets
NIS (Human sodium iodide symporter)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on VSV-mIFNβ-NIS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VSV-mIFNβ-NIS.